German TV show features mission of Alzheimer’s Germ Quest, Inc., reports Dr. Leslie Norins, CEO
German news show profiles American couple offering $1 million to any scientist who can prove a germ triggers Alzheimer's.
Several months ago, the German show’s producers became interested in fresh thinking about the possible triggers of AD and spotted a news item about the launch of AGQ’s project to help accelerate and deepen research on the likely participation of infectious agents. They sent a film crew to Naples for a detailed interview of the Norins’.
The entourage also went to a local senior center to observe and film how it conducts half-day classes, such as arts and crafts, for Alzheimer’s patients, so as to provide respite for their caregivers. The great impact made by meeting the patients led AGQ to propose the creation of “boot camps” to expose new AD researchers to the cognition deterioration the AD process inflicts on formerly vibrant seniors.
The German film crew remarked on how “open” American families were about a member’s having AD. They said that sometimes in Germany there is a kind of shame associated with the diagnosis, and so it is kept veiled in some cases.
Dr. Norins said that following the show’s broadcast in Germany, numerous emails were received from viewers there. He took this as a sign citizens there were as eager for research progress as those in the U.S.
Dr. Norins believes this show, and numerous other media inquiries he has received attest to the fact that the public is now demanding fresh approaches to AD research be funded, in addition to the older standbys of amyloid plaques and protein tangles.
Alzheimer’s Germ Quest, Inc. is a public benefit corporation headquartered in Naples Florida. Its mission is to accelerate and deepen scientific investigations into the possible role of infectious agents as the root cause of Alzheimer’s disease. It is the sponsor of the $1 Million Alzheimer’s Germ Quest Challenge Award for scientists. (ALZgerm.org).
Mollie Page
Page Print Communications
2397777243
email us here
Distribution channels: Healthcare & Pharmaceuticals Industry, Science, World & Regional
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release